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Systemic Teriparatide Administration Promotes Osseous
Regeneration of an Intrabony Defect: A Case Report
Jill D. Bashutski,* Janet S. Kinney,* Erika Benavides,* Samopriyo Maitra,† Thomas M. Braun,†
William V. Giannobile,*‡ Laurie K. McCauley,*x and Robert M. Eber*
Introduction: Teriparatide comprises the first 34 amino acids of parathyroid hormone and is a systemic anabolic agent
that is Food andDrugAdministration approved for the treatment of osteoporosis but not for periodontitis. To our knowledge, this
is the first clinical case report to document the treatment of a patient with severe periodontitis using an open-flap debridement
procedure in conjunction with teriparatide.
Case Presentation: A 45-year-old female patient was diagnosed with severe chronic periodontitis, including the pres-
ence of an intrabony defect on tooth #6. She received open-flap debridement surgery in conjunction with daily systemic admin-
istration of 20 mg teriparatide, oral vitamin D, and calcium supplements for 6 weeks. Radiographic, clinical, gingival crevicular
fluid (pyridinoline cross-linked carboxy-terminal propeptide of type I procollagen, procollagen type 1 N-propeptide, and osteo-
calcin), and serum parameters (parathyroid hormone, bone alkaline phosphatase, calcium, and 25-hydroxyvitamin D) were
assessed. Treatment outcomes were evaluated over 4 years, with successful radiographic and clinical results throughout the
follow-up period.
Conclusion: Teriparatide administration in conjunction with traditional open-flap debridement surgery offers potential for
the treatment of severe intrabony defects resulting from chronic periodontitis. Clin Adv Periodontics 2012;2:66-71.
Key Words: Bone regeneration; guided tissue regeneration; parathyroid hormone; periodontal attachment loss; periodontal
bone loss; teriparatide.
Background
Traditional periodontal surgical procedures, such as open-
flap debridement, most often result in tissue repair without
true regeneration of the lost tissues.1 Approaches to treat
periodontitis aimed at periodontal regeneration include
techniques, such as guided tissue regeneration (GTR) and
the use of local and systemic biologic modifiers, such as
platelet-derived growth factor, fibroblast growth factor,
low-dose doxycycline, and enamelmatrix derivative (EMD).
Although these regenerative approaches have shown success,
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none is capable of regenerating all types of periodontal
defects in every situation. Consequently, there is still a critical
need for a therapy that can enhance periodontal regeneration
in a predictable manner.
Parathyroid hormone (PTH) is an endogenous hormone
with both catabolic and anabolic properties in bone, de-
pending on the concentration and dosing regimen. Teripara-
tide contains the first 34 amino acids of the PTH molecule
and is the only commercially available pharmacologic agent
in the United States for treating osteoporosis that has been
shown in multicenter clinical trials to increase bone mass
lost as a result of osteoporosis.2 However, teriparatide is
not approved by the US Food and Drug Administration
for the treatment of periodontitis. Because osteoporosis
and periodontitis share aspects of their pathophysiology,3
there is justification for considering the treatment of peri-
odontal disease with therapies used for osteoporosis. This
led to the first human clinical trial using teriparatide to en-
hance healing in the oral cavity in 40 patientswith advanced
periodontal disease.4 The results of the clinical trial demon-
strated that patients taking teriparatide experienced signifi-
cantly greater radiographic linear bone gain, probing depth
(PD) reduction, and clinical attachment level (CAL) gain
compared to patients taking placebo. This case report doc-
uments the treatment and long-term follow-up of a patient
from this human clinical research trial who was treated
with teriparatide in conjunction with periodontal surgery
(ClinicalTrials.gov no. NCT00277706).
Clinical Presentation
A45-year-oldwhite female presented to theMichiganCen-
ter for Oral Health Research (Ann Arbor, Michigan) on
November 17, 2005, as part of a clinical research trial for
the treatment of an intrabony defect on the mesial aspect
of tooth #6 (#6M)associatedwith generalized severe chronic
periodontitis.4 The University of Michigan Institutional Re-
view Board approved the study. The patient was generally
healthy except that she had been recently diagnosed with os-
teopenia and was a former smoker (12 packs/year history;
quit in 1990). She reported no known drug allergies and
no current medications. Scaling and root planing of all teeth
wasperformed inOctober2005at theUniversityofMichigan
School of Dentistry. After initial therapy, PDs at tooth #6M
were 7 mmon both the mesio-buccal andmesio-palatal sur-
faces (Table 1). CALwas 9 mm on the mesio-buccal surface
and 7mmon themesio-palatal surface. Bleeding on probing
(BOP) was present in the area as well.
Case Management
On January 18, 2006, the patient received traditional open-
flap debridement surgery in the maxillary right quadrant
(surgeon was RME) (Fig. 1). During surgery, the intrabony
component of the defect measured 2mm on the buccal sur-
face and 3 mm on the lingual surface. Three days before
surgery, the patient began taking 20 mg teriparatide,
1,000 mg calcium, and 800 IU vitamin D daily and contin-
ued this regimen for 6 weeks.
Clinical Outcomes
Clinically, surgery resulted in satisfactory outcomes, with
periodontal PDs returning to healthy levels within 9
months. At 9 months, PDs were 2 mm on both the palatal
and buccal aspects of tooth #6M. CAL measured 6 mm on
the mesio-buccal surface and 4 mm on the mesio-palatal
surface. At both the 1 and 4 year follow-up appointments,
PDs were 3 mm and CAL was 7 mm on the mesio-buccal
surface and 6 mm on the mesio-palatal surface, indicating
long-term stability.
Standardized periapical radiographs were taken before
surgery, every 3 months afterward for 1 year, and again at
a 4-year follow-up (Figs. 2a through 2c). The initial defect
depth, as assessed radiographically, measured 6.1 mm from
the cemento-enamel junction (CEJ) to the base of the defect.
Maximum defect resolution was attained at 9 months post-
surgically, with 2.3 mm reduction in radiographic defect
depth, corresponding to near-complete osseous fill of the
intrabony defect based on intraoperative measurements.
Digital subtraction radiography was also used to confirm
TABLE 1 Clinical and Radiographic Results for Tooth #6M
Clinical and Radiographic
Measurements Baseline 1 Year 4 Year
Mesio-Buccal Mesio-Palatal Mesio-Buccal Mesio-Palatal Mesio-Buccal Mesio-Palatal
Clinical measurements
CAL (mm) 9 7 7 6 7 6
PD (mm) 7 7 3 3 3 3
BOP Yes Yes Yes No No No
Radiographic measurements
Intrabony defect depth (mm) 2.3 0 0
Alveolar bone height (CEJ to base of
defect,[mm])
6.1 3.8 4.0
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near-complete intrabony defect fill at 9 months (Fig. 2d).
This result was stable over a 4-year period, although the
crestal lamina dura appeared less dense than at 9 months
post-surgically. Cone beam computed tomography (CBCT)
scans taken before surgery and at 12months also confirmed
positive changes in the defectmorphology, includingmodest
vertical bone gain on tooth #6M (Figs. 2e and 2f).
As part of the research trial, serumcalcium, 25-dihydroxy-
vitamin D, PTH, and bone alkaline phosphatase were mea-
sured (Table 2). At the time of surgery, all serum parameters
were within normal limits. The effect of vitamin D and cal-
ciumsupplementation is discussed in detail in a separate pub-
lication.5 Six weeks after surgery, which corresponded to the
end of the teriparatide dosing regimen, the patient’s serum
bone alkaline phosphatase levels were slightly elevated, a
reflection of compliance with teriparatide administration.
Gingival crevicular fluid (GCF) samples of bone turnover
markers, includingpyridinoline cross-linked carboxy-terminal
propeptide of type I procollagen (ICTP), osteocalcin (OCN),
and procollagen type 1N-propeptide (P1NP),were evaluated
at baseline, 6 weeks, 6 months, and 1 year and analyzed by
standardmethodologies.6 In addition, a dual energy x-ray ab-
sorptiometry (DXA) scanwasperformed to evaluate systemic
bone mineral density before surgery and at 1 year. P1NP,
a marker of bone formation, was elevated at 6 weeks after
surgery. ICTP and OCN, markers of bone resorption and
bone turnover, respectively, decreased over time. The patient
hadTscores of1.2 (femur) and0.9 (spine) before surgery;
at 1 year, the T scores were 0.3 (femur) and 0.8 (spine).
Discussion
This case report demonstrates that teriparatide administration
in conjunction with periodontal surgery resulted in improved
clinical and radiographic outcomes that were sustained for
4 years. The patient in this report had greater improvement
in clinical and radiographic parameters than the average im-
provement reported inprevious studies.7,8Thiswasaproof-of-
principal study using an open-flap debridement protocol and
so the improvements noted as a result of teriparatide admin-
istrationwould ideally be optimized in future studies, perhaps
as an adjunct to GTR procedures. Future studies are also nec-
essary to determine the inclusion criteria, indications, and op-
timum dosing regimen for this treatment approach.
The effect of systemic teriparatide administration on the
periodontium in humans had not been documented before
this clinical trial,4 so little is known about its therapeutic po-
tential for the treatment of oral conditions. One study eval-
uated the ability of teriparatide to aid in fracture repair and
found that it preferentially enhanced bone remodeling in
areas of high turnover, such as fracture and surgical sites.9
In an animal study of mandibular fracture healing, systemic
teriparatide administration enhanced early-phase wound
healing.10 Another recent study assessed the osteogenic effect
of teriparatide on various parts of the human skeleton and
found that the mandible had one of the highest activity
rates.11 This may explain why systemic teriparatide adminis-
tration resulted in such high clinical success when used as an
adjunct to an oral surgical procedure. Additionally, this sug-
gests that the oral cavity may be one of the most receptive
sites in the body for teriparatide response.
Side effects of systemic teriparatide administration include
dizziness, nausea, swelling at the injection site, and joint
pain. In preclinical studies,12 therewas an increased incidence
of osteosarcoma in teriparatide-treated rats at doses much
higher and much longer duration than used for this applica-
tion. The relevance of these findings is uncertain because
an increased incidence of osteosarcoma has not been found
in humans treated with teriparatide, but it is currently
FIGURE 1a Preoperative image of tooth #6. 1b Open-flap debridement with an intrabony defect noted on tooth #6M. 1c Sutured flap using simple, interrupted
sutures. 1d One week postoperative healing is within normal limits. 1e After 12 months of healing, PDs were reduced to 3 mm. 1f Four years after surgery, PDs
on tooth #6M remain stable with no BOP.
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contraindicated for patients at increased baseline risk of os-
teosarcoma. In addition, the cost of teriparatide administra-
tion in its current form is very high relative to other treatment
regimens. Periodontitis is a localized disease compared to os-
teoporosis, and so future strategies to optimize teriparatide
administration could include local concentration in sites of
osseous wound healing to maximize benefits and minimize
systemic effects. However, it is challenging to develop a local
delivery system that is able to deliver teriparatide at low and
intermittent doses, which is what is required to achieve an-
abolic effects. Several local delivery systems have been devel-
oped already and tested in preclinical animal models with
varying rates of success.13,14 In foxhounds, an arginine–gly-
cine–aspartic acid modified polyethylene glycol-based ma-
trix containing covalently bound peptides of PTH resulted
in significantly more new bone formation but not more
bone-to-implant contact after 4 and 12 weeks.13 In contrast,
systemic PTH administration in a rat model was found to
stimulate local bone formation, whereas local delivery of
PTH using b-tricalcium phosphate did not.14
There is a clear need for improved therapeutics that can
target localized osseous healing as desired for periodontal
regenerative outcomes. Using systemic teriparatide as an ad-
junct to periodontal surgerymay be a promising therapeutic
option to promote osseous regeneration with long-term re-
sults. However, it is important to note that the ability of ter-
iparatide to promote regeneration has not been verified
histologically. Furthermore, future large-scale clinical trials
are required to confirm the benefits of teriparatide on osse-
ous healing and to optimize treatment protocols. n
FIGURE 2 Imaging of the defect presented in
Figure 1. 2a Initial radiograph illustrating an
intrabony defect on tooth #6M. 2b Radiograph
at 9 months demonstrating significant defect fill.
2c Four years after surgery, significant bone fill
remains. 2d Digital subtraction radiography
shows the area and degree of bone fill on tooth
#6M from baseline to 9 months. 2e Recon-
structed CBCT image of the maxillary right
quadrant before surgery. 2f Reconstructed
CBCT image of the maxillary right quadrant 1
year postoperatively. In all panels, white arrows
represent the baseline bone level as well as the
current bone level. Black arrows illustrate the
reference point from which measurements were
obtained.
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Summary
Why is this case report new
information?
j To our knowledge, this is the first fully documented case of
systemically administered teriparatide to aid in the surgical treatment
of periodontitis.
What are the keys to successful
management of this case?
j A 6-week dosing regimen of teriparatide resulted in long-lasting
clinical improvement, suggesting that this is a promising therapeutic
option for patients with severe periodontitis.
What are the primary limitations to
success in this case?
j Open-flap debridement surgery was used as part of this proof-of-
principle study. In the future, other surgical options could be explored
that may yield better outcomes.
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TABLE 2 Serum, GCF, and DXA Results
Serum, GCF and
Radiographic Assessments Baseline 6 Weeks 6 Months 12 Months
Serum biomarkers
PTH (pg/mL) 36 N/A N/A N/A
Calcium (mg/dL) 9.7 9.7 9.1 N/A
25-dihydroxyvitamin D (ng/mL) 33 24 34 N/A
Bone alkaline phosphatase (mg/L) 7.4 8.7 7.8 N/A
GCF
ICTP (pg/mL) 90 67 46 21
OCN (pg/mL) 35 29 18 12
P1NP (pg/mL) 1,151 1,296 394 97
Systemic bone mineral density (assessed using DXA)
T score, spine 0.9 N/A N/A 0.8
T score, femur 1.2 N/A N/A 0.3
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